SCHEMBL3096356

SCHEMBL3096356

CC(C)(Cc1cc2nc(Cl)ccc2n1Cc1ccc(Cl)cc1)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TBXA2R P21731 10/20 0.64
PTGES2 Q9H7Z7 8/20 0.51
KDM4E B2RXH2 2/20 0.51
CYP1A2 P05177 2/20 0.51
CYP3A4 P08684 2/20 0.51
MAPT P10636 2/20 0.51
CYP2C9 P11712 2/20 0.51
HPGD P15428 2/20 0.51
HSD17B10 Q99714 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
TSHR P16473 1/20 0.51
CYP2C19 P33261 1/20 0.51
HIF1A Q16665 1/20 0.51
ALOX5AP P20292 3/20 0.51
PTGES O14684 2/20 0.49
MEN1 O00255 1/20 0.46
USP2 O75604 1/20 0.46
TP53 P04637 1/20 0.46
POLB P06746 1/20 0.46
ALOX5 P09917 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3100317 0.87 TBXA2R (0.59) TBXA2RPTGES2KDM4ECYP1A2CYP3A4
SCHEMBL3103170 0.86 TBXA2R (0.48) TBXA2RPTGES2KDM4ECYP1A2CYP3A4
SCHEMBL9581675 0.81 ALOX5AP (0.54) TBXA2RPTGES2KDM4ECYP1A2CYP3A4
SCHEMBL3105496 0.79 ALOX5AP (0.58) TBXA2RCYP3A4CYP2C9ALOX5APALOX5
SCHEMBL3088456 0.77 TBXA2R (0.48) TBXA2RPTGES2KDM4ECYP1A2CYP3A4
SCHEMBL3094540 0.75 TBXA2R (0.46) TBXA2RPTGES2KDM4EMAPTTDP1
SCHEMBL6112133 0.75 ALOX5AP (0.60) CYP3A4CYP2C9ALOX5APALOX5PTGS2
SCHEMBL3535449 0.73 PPARG (0.56) TBXA2RKDM4EMAPTHPGDHSD17B10
SCHEMBL12966490 0.73 TBXA2R (0.47) TBXA2RTP53POLBRAB9A
SCHEMBL2109026 0.72 ALOX5AP (0.77) CYP3A4CYP2C9ALOX5APALOX5PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1933842-B1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS PANMIRA PHARMACEUTICALS LLC (US) 2012-10-03 EP disclosed
US-7795274-B2 5-lipoxygenase-activating protein (FLAP) inhibitors AMIRA PHARMACEUTICALS INC. (US) 2010-09-14 US disclosed
US-7795274-B2 5-lipoxygenase-activating protein (FLAP) inhibitors AMIRA PHARMACEUTICALS INC. (US) 2010-09-14 US disclosed
US-7795274-B2 5-lipoxygenase-activating protein (FLAP) inhibitors AMIRA PHARMACEUTICALS INC. (US) 2010-09-14 US disclosed
US-20080227807-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2008-09-18 US disclosed
US-20080227807-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2008-09-18 US disclosed
US-20080227807-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2008-09-18 US disclosed
US-7405302-B2 5-lipoxygenase-activating protein (FLAP) inhibitors AMIRA PHARMACEUTICALS, INC. (US) 2008-07-29 US disclosed
US-7405302-B2 5-lipoxygenase-activating protein (FLAP) inhibitors AMIRA PHARMACEUTICALS, INC. (US) 2008-07-29 US disclosed
US-7405302-B2 5-lipoxygenase-activating protein (FLAP) inhibitors AMIRA PHARMACEUTICALS, INC. (US) 2008-07-29 US disclosed
US-20070123522-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-05-31 US disclosed
US-20070123522-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-05-31 US disclosed
US-20070123522-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-05-31 US disclosed
WO-2007047207-A2 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227807-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 TBXA2R 97/4885PTGES2 29/4885KDM4E 2621/4885
US-20070123522-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 TBXA2R 97/4885PTGES2 29/4885KDM4E 2621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.